Home
overview

The conference listed on this page was held in 2009. For information on the 2010 conference go to www.smi-online.co.uk/2010europricing.asp  

European Pharmaceutical Pricing & Reimbursement Conference 2010

  

 

 

  • Hear about the impact of different European P&R systems on the industry
  • Understand the effect of pricing and reimbursement on the internal market
  • Learn about the Integration of Market Access during clinical development
  • Gain insights into processes and methods used for technology appraisal

 

 Vice Presidents, Directors, Managers and Heads of:

  • Pricing and Reimbursement
  • Health Economics
  • Government Affairs
  • Strategic Pricing
  • Price Monitoring
  • Market Access
  • International Trade
  • Parallel Trade
  • Business Strategy
  • Sales and Marketing
  • Corporate Strategy
  • Regulatory Affairs
  • Outcomes Research
  • Legal

 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Donald Macarthur

Donald Macarthur, Global Pharmaceutical Business Analyst,

9:10 IMPACT OF DIFFERENT EUROPEAN PRICING AND REIMBURSEMENT

Rainer Walenta

Rainer Walenta, Director, Global Pricing and Reimbursement, Solvay Pharmaceuticals

  • Impact of international price referencing on local pricing and reimbursement
  • Launch strategies and launch sequencing
  • Will there be a unified European pricing scheme?
  • 9:50 DRUG REPOSITIONING STRATEGIES – PRICING AND MARKET ACCESS

    Susana Murteira

    Susana Murteira, Head of Pricing and Reimbursement, H. Lundbeck

  • Drug reformulation as a first line option
  • Review of case studies
  • Dual indication pricing – regulatory vs. market access possibilities
  • Paralel trade considerations
  • Fixed drug combinations – an analysis from a pricing and reimbursement perspective
  • 10:30 Morning Coffee

    11:00 CHANGES IN THE UK MARKET AND THE PPRS

    Phill O'Neill

    Phill O'Neill, Head of Information and Analysis, Office of Health Economics

  • Principles and philosophy of the UK PPRS
  • Adoption of mechanisms to incorporate value into the UK market
  • Generic substitution
  • Evolution of the branded market in the UK
  • Forecast to 2013
  • 11:40 THE UK PHARMACEUTICAL PRICE REGULATION SCHEME

    Donald Macarthur

    Donald Macarthur, Global Pharmaceutical Business Analyst,

  • Principles, evolution and contents of the PPRS
  • What has changed, what has not
  • Likely impact of novel features in the 2009 Scheme
  • Inter-relationship with NICE
  • The alternative statutory scheme
  • 12:20 Networking Lunch

    13:50 EVIDENCE-BASED MEDICINE IN AN EVOLVING LANDSCAPE FOR GLOBAL MARKET ACCESS

    Lujing Wang

    Lujing Wang, Practice Executive, Pricing and Reimbursement Practice, Campbell Alliance

  • Key market access barriers and how they vary by geographic market and disease area
  • Increasing focus on evidence based medicine and HTA
  • The evolving requirement for evidence to support product reimbursement and access
  • How these trends are shaping pharmaceutical markets and how the evidence base is coming
  • How to think more strategically about how to address market access challenges
  • Better integrating evidence generation and value substantiation into the commercial planning process  
  • Key Takeaways for commercial planners
  • 14:30 CANADA: THE CHANGING PRICING AND REIMBURSEMENT ENVIRONMENT

    Neil Palmer

    Neil Palmer, President and Principal Consultant, PDCI Market Access

  • Overview of Canadian healthcare system and pharmaceutical funding
  • Price regulation and the new guidelines of the Patented Medicine Prices Review Board (PMPRB)
  • HTA and the role of CADTH and the Common Drug Review
  • Provincial and private reimbursement schemes and the growth of risk sharing agreements
  • Parallel trade: decline of the Canadian internet pharmacy business, is US importation still feasible?
  • Outlook for P&R in Canada
  • 15:10 Afternoon Tea

    15:40 DECISION MAKING AT NICE

    Elisabeth George

    Elisabeth George, Associate Director - Appraisals , National Institute for Clinical Excellence

  • Processes and methods used for technology appraisal
  • The role of cost effectiveness and other considerations
  • Overview of decisions made so far
  • Implementing the PPRS in technology appraisals
  • 16:20 COMPARATIVE EFFECTIVENESS RESEARCH, COST-EFFECTIVENESS

    Neil Hawkins

    Neil Hawkins, Research Fellow and Health Economist, Centre for Health Economics

  • The demand curve and optimum pricing
  • The role of comparative effectiveness research
  • The role of cost-effectiveness modelling
  • The value of information
  • 17:00 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Colin Wight

    Colin Wight, Founder and Chief Executive Officer, GalbraithWight

    9:10 PRICING AND REIMBURSEMENT IN EUROPE: THE ROLE OF INDUSTRY

    9:50 MANAGING PRICE THROUGHOUT THE LIFECYCLE OF A PRODUCT

    Martin  Egler

    Martin Egler, Director, Pharmacoecomonics and Pricing & Reimbursement, Merz Pharmaceuticals

  • Measurement of a successful P&R Strategy
  • What payers are looking for
  • Commonly used techniques
  • Pricing and lifecycle management
  • 10:30 Morning Coffee

    11:00 ADDRESSING HEALTH TECHNOLOGY ASSESSMENT/HEALTH ECONOMICS

    Patrick Mollon

    Patrick Mollon, Former Associate Director, Global Medical and Outcomes Research, Pfizer

  • Drivers for incorporating HTA/HE early into development
  • Activities to undertake, issues to address
  • Strategic considerations
  • Organisational aspects
  • 11:40 DEFINING MARKET ACCESS STRATEGIES & UNDERSTANDING COMPANY CAPABILITY REQUIREMENTS

    Colin Wight

    Colin Wight, Founder and Chief Executive Officer, GalbraithWight

  • The true scope of market access and timelines
  • Planning
  • Understanding Payer needs
  • Innovative approaches to pricing.
  • Impact of current risk share agreements and future recommendations
  • Understanding the capability requirements for market access
  • 12:20 Networking Lunch

    13:50 THE RISE OF A COMMON EU ASSESSMENT ON DRUGS

    Ad Schuurman

    Ad Schuurman, Head of Reimbursement, Dutch Health Care Insurance Board (CVZ)

  • Collaboration until now
  • Recent developments
  • EMEA, MEDEV, EUnetHTA
  • The way forward
  • 14:30 EU COOPERATION ON HEALTH TECHNOLOGY ASSESSMENT

    Jérôme Boehm

    Jérôme Boehm, Policy Officer, Health and Consumers Directorate General, European Commission

  • Objectives from an EU perspective
  • Possible work areas
  • Working with stakeholders
  • 15:10 COLLABORATION WITH MARKETING: GROWING PAINS?

    Gurmit Sandhu

    Gurmit Sandhu, Independent Consultant in Launch Management and Market Access , Switzerland

  • Marketing: opportunities & challenges
  • Understanding mindset of global marketers
  • Engaging marketers
  • Deliver value through collaboration
  • 15:50 Chairman’s Closing Remarks

    16:00 Afternoon Tea and Close of Conference

    +

    Workshops

    Cooperation with Payors as a Means for Attaining Reimbursement
    Workshop

    Cooperation with Payors as a Means for Attaining Reimbursement

    Courtyard by Marriott - Munich City Centre
    27th October 2009
    Munich, Germany

    Courtyard by Marriott - Munich City Centre

    Schwanthalerstrasse 37
    Munich Bavaria 80
    Germany

    Courtyard by Marriott - Munich City Centre

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.